To determine the impact of baseline TAP1 and TAP2 downregulation in treatment-specific outcomes, we studied the overall survival (OS) of patients in the NSCLC cohorts treated with standard chemotherapy and/or surgery (cohorts #1, #2 and #3) or after treatment with PD-1 axis blockers (cohort #4). This evidence concerns the gene TAP2 and non-small cell lung carcinoma.